INTERVIEWS

Dr. Michelle Niedziela, PhD, Behavioral Neuroscience Expert and VP of Research and Innovation at HCD Research discusses a first-of-its-kind study for Jiffy Lube that used brain activity to uncover the connection people have with their cars and how the condition of their vehicle affects their well-being.

Nicole Andrews, Co-Founder, STAAR Ovarian Cancer Foundation ​which ​specifically exists to fund life-saving research for women with low-grade serous ovarian cancer, a rare and underfunded subtype, discusses the global campaign launched on World Ovarian Cancer Day by STAAR in partnership with Cure Our Ovarian Cancer, a global research charity, that features women with low-grade serous ovarian cancer.

Dan Cua, PhD, Vice President, IL-23 Pathway Leader, Janssen Research & Development, LLC discusses new data showing that TREMFYA binds to both inflammatory cells and IL-23, supporting a hypothesis for a differentiated mechanism of action. These in vitro studies suggest that TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local activation of cells that drive inflammation in immune-mediated diseases like psoriasis and psoriatic arthritis. These data were presented at the Society for Investigative Dermatology (SID) 2022 Meeting.

Dr. Vivek Lal, CEO and Founder of ResBiotic, discusses the first-of-its-kind supplement that can target the gut-lung axis with clinically validated probiotic strains and bioactive botanicals. He shares ResBiotic’s origin story and key findings that helped advance the gut-lung axis science, the creation of a proprietary probiotic blend, and the ongoing and planned studies that will further test the effects of this novel formulation. 

Scott Rombach, CEO of Specialist Direct discusses how telepathology and telehealth can make all the difference by enabling the faster evaluation of donated organ tissue, leading to increased recovery rates, reduced organ discards, as well as significant cost savings. As a leader in providing telehealth solutions in the organ transplant sector, Specialist Direct has partnered with organ procurement organizations (OPOs) across the country to facilitate the organ transplantation process with its telepathology solutions.

Dr. Bruce Dorr, OB/GYN at Littleton GYN & Wellness/Right Balance Hormone Health Center discusses menopause, the wide range of symptoms, why women and healthcare professionals alike often don’t recognize or misdiagnose symptoms of menopause, what every health care practitioner should consider when seeing female patients ages 45 years and older, and hormone therapy. He talks about a recent survey that showed that 4 out of 10 women over 50 say that menopause symptoms have interfered with their work or career at least once a week.

Dr. Andrew Miller is the Founder and Chief Operating Officer of Karuna Therapeutics and  primary inventor of the company’s lead product candidate, KarXT (xanomeline-trospium). Dr. Miller  discusses this  investigational treatment, which offers a potential new approach to treating schizophrenia and other neuropsychiatric conditions, including psychosis in Alzheimer’s disease, by way of its unique differentiated mechanism of action that does not rely on targeting dopaminergic or serotonergic pathways, as  currently available treatments do. If successfully developed and approved, KarXT has the potential to usher in the newest generation of antipsychotics for patients and ultimately change the treatment paradigm as we know it.  

Asher Brass, Head of Cyber Network Analysis Team at Cynerio, the leading provider of Healthcare IoT cybersecurity and asset management solutions, discusses the company’s recent discovery of five zero-day vulnerabilities collectively known as JekyllBot:5, that affect commonly used Aethon TUG robots found in hundreds of hospitals worldwide, and how hospitals can proactively mitigate cybersecurity risks. He also talks about the results of Cynerio’s recent State of Healthcare IoT Device Security report which shows that 53% of connected medical devices and other IoT devices in hospitals, and discusses approaches that must be used to protect highly vulnerable hospital environments.

Dr. Zobair Younossi, Chairman, Department of Medicine, Inova Fairfax Medical Campus, and Dr. Chuck Cooper, Chief Medical Officer, Siemens Healthcare Diagnostics at Siemens Healthineers discuss non-alcoholic steatohepatitis (NASH), a disease characterized by inflammation of the liver, and the Enhanced Liver Fibrosis (ELF™) Test, the only non-invasive blood test granted authorization by the FDA to assess the risk of disease progression in NASH patients. This test can potentially improve outcomes for millions of people with advanced liver disease.

Milind Desai, M.D., MBA, the director of clinical operations, Heart, Vascular & Thoracic Institute, Cleveland Clinic, discusses the recent approval of Camzyos, the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (HCM). He also shares insight into what this treatment option means for obstructive HCM patients and the clinical impact of this approval.